From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.
Walling
Jackie
J
Department of Medicine, University of Bristol, UK. Jackie@jwalling.fsnet.co.uk
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001692:Biological Transport; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm; D005493:Folic Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D005971:Glutamates / Q000494:pharmacology / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D000068437:Pemetrexed; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D008727:Methotrexate